DailyIQ
Last updatedUpdating…

RMD·ResMed Inc.

$235.40
+0.36 (+0.15%)
After Hours
High
$237.06
Open
$235.58
Market Cap
33.05B
52W High
$280.01
Low
$232.76
P. Close
$235.40
P/E
21.70
52W Low
$180.26
Fwd P/E
17.76
DailyIQ Est.
$253.05
Inst. Ownership
34.9%
Short Interest
9.08%
Days to Cover
9.9
Div. Yield
1.05%
Next Ex-Div
~Nov 19
Div. Growth
12+ yrs
Technical Score (1D)
19
BEARISH
News Sentiment
53
MIXED
On Oct 13, Mizuho raised its price target for ResMed to $240 from $235, indicating a modest bullish outlook. The bank maintained an overweight rating and noted that the mean target across analysts was $260.89. The adjustment was presented as a signal of confidence in ResMed’s near‑term performance. No other developments were reported for that date.
LOW TARGET
$175 -25.6%
2 analysts
MEAN TARGET
$251 +6.5%
17 analysts
HIGH TARGET
$320 +36.0%
8 analysts
PRICE RANGE
$175.00 - $320.00
SB / B / H / S / SS
4/9/12/1/1
DAILYIQ EST.
$253.05 (+7.5%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Website
Symbol
RMD
Description
ResMed Inc. is a global medical technology company specializing in the development and distribution of devices and software solutions focused on respiratory health. The company's core business centers on diagnosing, treating, and managing sleep apnea and other breathing disorders through its Sleep and Breathing Health segment. ResMed offers a range of diagnostic devices, including portable options for both in-clinic and at-home use, alongside cloud-based platforms like AirView that facilitate remote patient monitoring and device management. Complementing its hardware, ResMed provides software solutions, such as myAir, to enhance patient engagement and compliance, as well as solutions for home medical equipment providers. Through its comprehensive product offerings, ResMed aims to improve patient outcomes and streamline healthcare workflows within the respiratory care market.
Bought (1Y)
0 shares
$0
Sold (1Y)
34,193.742 shares
$7.4M
Farrell Michael J.Chairman and CEO
Option Exercise4,991 shares2026-10-07
Farrell Michael J.Chairman and CEO
Sell4,991 shares2026-10-07
Farrell Michael J.Chairman and CEO
Option Exercise4,991 shares2026-10-07
Farrell Michael J.Chairman and CEO
Option Exercise4,991 shares2026-09-08
Farrell Michael J.Chairman and CEO
Sell4,991 shares2026-09-08
80/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
61.1%
Net Margin
26.9%
Revenue CAGR
11.3%
Current Ratio
3.10x
Debt / Equity
0.10x
Return on Equity
23.1%
Earnings Summary
ResMed Inc. is a global medical technology company focused on respiratory health, offering diagnostic devices, CPAP/APAP therapy, and cloud‑based platforms such as AirView and myAir. Operating in the healthcare medical instruments sector, ResMed serves patients and providers worldwide with a comprehensive product ecosystem. The company’s recent earnings show EPS of $2.43 in Q4 2024, $2.37 in Q1 2025, $2.55 in Q2 2025, $2.55 in Q3 2025, $2.86 in Q3 2026, and $2.95 in Q4 2026, each beating estimates and demonstrating a steady upward trend. Revenue rose from $1.282 bn in Q4 2024 to $1.431 bn in Q4 2026, reflecting a 9 % year‑over‑year jump in the latest quarter driven by strong demand for CPAP/APAP devices and accessories. Historically, ResMed has posted consistent revenue growth of 7‑10 % annually while maintaining EPS beats in most quarters, indicating robust pricing power and a healthy recurring revenue mix. Recent news reports a 9 % YoY revenue increase to $1.5 bn, with device revenue up 6 % in the Americas and total Sleep and Breathing Health revenue up 8 %, reinforcing its market leadership. Key will be how ResMed’s recurring revenue translates into cash flow and margin expansion amid competitive pressures and potential regulatory changes in key markets.

EPS

EstBeatMiss
$2.27$2.46$2.66$2.85$3.04Q1'25Q2'25Q3'25Q3'26Q4'26Q1'27
QtrEstActual+/−
Q1'27$2.67 - -
Q4'26$2.92$2.95+1.1%
Q3'26$2.80$2.86+2.2%
Q3'25$2.50$2.55+2.1%
Q2'25$2.48$2.55+2.8%
Q1'25$2.36$2.37+0.4%

Revenue

EstBeatMiss
$1.3B$1.3B$1.4B$1.4B$1.5BQ1'25Q2'25Q3'25Q3'26Q4'26Q1'27
QtrEstActual+/−
Q1'27$1.4B - -
Q4'26$1.5B$1.5B-0.7%
Q3'26$1.4B$1.4B+0.6%
Q3'25 - $1.3B -
Q2'25 - $1.3B -
Q1'25 - $1.3B -

Market Data

RMD Stock Snapshot

BEARISH19/100
$235.29−$0.11 (0.0%)
Market cap
33.05B
P/E ratio
21.7
Day range
$232.76 – $237.06
News sentiment
53/100 · Neutral
Analyst target
$250.52 (+6.5%)
Consensus
Hold · 27 analysts
52-week range+30.5% off low · -16.0% from high
$180.26$280.01
Price $235.29 DailyIQ Est. $253.05

RMD is on the weaker side of its setup, with little confirmation for a reversal yet. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into RMD?

CHEAP

At today's price, ResMed Inc. needs to grow free cash flow about 6.7% a year for the next 10 years to justify its valuation at a 8.60% cost of capital. Over its actual history it has compounded free cash flow at 12.6% a year, so the market is asking for 5.8 percentage points below its own delivered rate. On that basis RMD looks priced below what its own growth record supports.

Implied FCF growth
6.7%
Historical FCF CAGR
12.6%
Growth gap
-5.8 pts
Verdict
CHEAP
Discount rate (WACC)
8.60%
Beta
0.69

Behaviour On Record

What RMD's own history says about today's numbers

Realized volatility (21d)
17.9% 22nd pct
Below its peak
-21.0%
vs 200-day average
+4.4%
Up days (1y)
48%

ResMed Inc. is currently running 17.9% annualised volatility over the last 21 sessions. Measured against RMD's own 13 years of daily returns rather than a market-wide average, that is the 22nd percentile — unusually subdued by its own history, against a typical reading of 24.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RMD is trading -21.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -19.5%, and the deepest was -44.1% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +4.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 45th percentile — close to the gap it normally carries. Over the past year RMD closed higher on 48% of sessions, and it is currently 5 sessions into a rising streak.

On October specifically: over 13 years of records, RMD finished the month higher 7 of 13 times, with a median return of +0.3% and an average of +1.7%. Its strongest month historically has been July at +5.9% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RMD has opened more than 2% away from the prior close in 121 of 3,267 sessions (3.7% of the time), with the largest gaps running +10.4% and -9.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against RMD's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RMD's sector?

ResMed Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for RMD?

CallsPuts

For ResMed Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.52), with at-the-money implied volatility around 42.1%. The options market is pricing roughly a ±3.1% move by that expiry — a range of about $227.62–$242.38.

Put/call ratio (2026-10-16)
0.52
ATM implied volatility
42.1%
Total open interest
3,442
Expected move by 2026-10-16
±3.1% ($227.62–$242.38)

Analyst Rating Changes

Are analysts turning bullish or bearish on RMD?

RBC Capital most recently upgraded ResMed Inc. to Outperform on Sep 15, 2026 with a price target of $262 (from $244). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
RBC Capital — Outperform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Sep 15, 2026RBC CapitalUpgradeSector Perform → Outperform$244 → $262
Aug 31, 2026KeybancMaintainedOverweight$255 → $267
Aug 19, 2026Rothschild & CoInitiatedNeutral$230
Aug 7, 2026RBC CapitalMaintainedSector Perform$234 → $244
Aug 7, 2026Piper SandlerMaintainedNeutral$233 → $225
Aug 7, 2026KeybancMaintainedOverweight$260 → $255
Aug 7, 2026Wells FargoMaintainedEqual-Weight$225 → $215
Jul 15, 2026MizuhoMaintainedOutperform$235 → $220
Jul 13, 2026CitigroupDowngradeBuy → Neutral$270 → $235
Jul 10, 2026JefferiesMaintainedHold$240 → $225
Jul 8, 2026RBC CapitalMaintainedOutperform$321 → $276
Jul 8, 2026Wells FargoMaintainedEqual-Weight$227 → $225

Peers & ETF holders

RMD peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

53/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Mizuho lifted its price target for ResMed (RMD) to $240 from $235, reflecting a modest bullish outlook. The bank maintains an overweight rating and a mean target of $260.89 across analysts. The adjustment signals confidence in RMD’s near‑term performance but does not indicate a major shift in valuation.
What did this article say?
ResMed (NYSE:RMD) released the transcript of its fourth‑quarter 2026 earnings call on October 12. The transcript includes management commentary on financial performance, guidance, and strategic initiatives. No specific financial figures or forward guidance were disclosed in the provided excerpt. The release offers investors insight into the company’s operational priorities and market outlook. The document is a routine disclosure with no immediate material impact on RMD’s valuation.
What did this article say?
On October 7, 2026, ResMed CEO Michael J. Farrell sold 4,991 shares worth $1,129,637, as reported in a Form 4 filing. The sale reduced his direct holdings to 479,803 shares, while he retained control of 481,893 shares overall. The transaction was disclosed to the SEC and made public via Yahoo Finance. The sale may signal insider concern about the company’s near‑term prospects, though the volume is modest relative to total shares outstanding.
What did this article say?
ResMed (RMD) met ChartMill’s Best Dividend criteria on October 7, citing a sustainable payout ratio, robust profitability, and a solid balance sheet. The assessment highlighted the company’s ability to maintain dividend payments without compromising financial health. This endorsement reinforces investor confidence in RMD’s long‑term income potential.
What did this article say?
The article reviewed ResMed’s recent performance, noting a modest 2.7% loss and a 8.9% constant‑currency revenue growth over two years. It highlighted the company’s stable free‑cash‑flow margin and global expansion potential. The piece offered a balanced view, suggesting investors weigh the stock’s current valuation against its long‑term growth prospects. No new material catalysts or earnings surprises were reported, leaving the outlook unchanged.
What did this article say?
Resmed (RMD) announced that it would publish its first quarter fiscal 2027 financial and operational results on October 29, 2026, following the New York Stock Exchange close. The company will host a webcast to discuss the results and any forward‑looking information. The announcement provides a schedule for the earnings release and webcast but does not include any guidance or performance updates.
What did this article say?
ResMed (RMD) continues to capitalize on the expanding global obstructive sleep apnea (OSA) market, driven by heightened awareness and penetration. The company’s robust product lineup, centered on the AirSense CPAP/APAP platform, supports recurring revenue through devices and accessories. With a strong portfolio and market leadership, RMD is well positioned for sustained growth in the coming fiscal periods.
What did this article say?
RMD received a bullish upgrade from RBC Capital, moving from Sector Perform to Outperform and raising its price target to $262 from $244. The upgrade cites expanding demand for sleep apnea devices and RMD’s position as a leading provider in respiratory care. Analysts expect the company to capture additional market share as global awareness of obstructive sleep apnea grows. This upgrade signals confidence in RMD’s growth trajectory and could lift investor sentiment.
What did this article say?
RBC Capital’s analyst Craig Wong‑Pan has upgraded ResMed (RMD), lifting the price target and sparking a rally in the stock. The upgrade follows a bullish outlook on the company’s growth prospects, particularly in its sleep‑apnea and respiratory therapy segments.
What did this article say?
RBC Capital has upgraded ResMed (RMD) to an Outperform rating, lifting the target from a Sector Perform stance. The brokerage cites stronger earnings guidance, a robust product pipeline, and favorable market positioning as key drivers. This upgrade signals renewed confidence in RMD’s growth prospects and may influence short‑term trading activity.

Technical Analysis

Real-time indicators across multiple timeframes

19
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $10.43B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell18,882,40313.41%$4.55B2026-01-29
BlackRock, Inc.▲ Buy12,317,1948.75%$2.40B2026-08-07
Geode Capital Management, LLC▼ Sell4,352,3203.09%$845.16M2026-08-12
Invesco Ltd.▲ Buy2,063,5781.47%$402.15M2026-08-14
Morgan Stanley▼ Sell1,928,9311.37%$375.91M2026-08-13
Northern Trust Corp▼ Sell1,696,6741.21%$330.65M2026-08-13
Goldman Sachs Group Inc▲ Buy1,160,4260.82%$226.14M2026-08-14
AQR Capital Management LLC▲ Buy910,6230.65%$177.14M2026-08-14
JPMorgan Chase & Co▲ Buy833,5360.59%$165.40M2026-08-12
Bank of America Corp▼ Sell775,4240.55%$151.11M2026-08-14
Citigroup Inc▲ Buy774,4250.55%$150.92M2026-08-03
Norges Bank▼ Sell664,7140.47%$129.54M2026-08-12
AllianceBernstein L.P.▲ Buy491,4720.35%$110.33M2026-08-14
Citadel Advisors LLC▲ Buy508,2840.36%$99.05M2026-09-02
Two Sigma Investments, LP▲ Buy411,0360.29%$80.10M2026-08-14
Wells Fargo & Company▲ Buy230,9140.16%$45.00M2026-08-14
FMR LLC (Fidelity)▼ Sell216,6300.15%$42.22M2026-08-13
Millennium Management LLC▲ Buy204,7310.15%$39.90M2026-08-14
Man Group plc▲ Buy126,2910.09%$24.61M2026-08-14
Gotham Asset Management, LLC▼ Sell82,8280.06%$16.14M2026-08-14
Wellington Management Group LLP▲ Buy81,1840.06%$15.82M2026-08-14
Prudential Financial Inc▼ Sell74,7670.05%$14.57M2026-08-12
Susquehanna International Group, LLP▲ Buy71,7540.05%$13.98M2026-08-14
Bridgewater Associates, LP▲ Buy67,3810.05%$13.13M2026-08-14
Fisher Asset Management, LLC▼ Sell52,5110.04%$10.23M2026-08-04
Q2 2026 flow:2.21M sh bought ($434.47M)1.45M sh sold ($283.25M)net +757.8K sh (+$151.22M)
Congressional Trading Activity
9 disclosed trades · ~$72.0K est. traded value · 3 buys, 6 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Kelly Louise MorrisonHouseMN03▼ Sell$1K - $15K2025-06-042025-06-18
Kelly Louise MorrisonHouseMN03▼ Sell$1K - $15K2025-04-282025-05-13
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-01-132025-02-13
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-05-032026-08-05
Tommy TubervilleSenateAL▲ Buy$1K - $15K2023-10-172023-11-16
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-10-052022-11-10
Tommy TubervilleSenateAL▲ Buy$1K - $15K2022-03-302022-04-08
Tommy TubervilleSenateAL▼ Sell$1K - $15K2021-10-262021-11-10